Clinical Trial Update: Dual Modulation of Sigma-1 and NMDA Receptors in the Treatment of Schizophrenia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating dual modulation of sigma-1 and NMDA receptors for schizophrenia, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Snippet

Sponsor: China Medical University Hospital | Conditions: Schizophrenia | Phase 2 | Status: RECRUITING